|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRDN |
Gene summary for TRDN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRDN | Gene ID | 10345 |
| Gene name | triadin | |
| Gene Alias | CPVT5 | |
| Cytomap | 6q22.31 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q8IVK2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10345 | TRDN | C08 | Human | Oral cavity | OSCC | 1.20e-07 | 1.00e-01 | 0.1919 |
| 10345 | TRDN | SYSMH3 | Human | Oral cavity | OSCC | 3.63e-02 | -1.00e-01 | 0.2442 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005123518 | Oral cavity | OSCC | maintenance of location | 182/7305 | 327/18723 | 6.16e-10 | 1.58e-08 | 182 |
| GO:005165120 | Oral cavity | OSCC | maintenance of location in cell | 121/7305 | 214/18723 | 1.39e-07 | 2.32e-06 | 121 |
| GO:00070294 | Oral cavity | OSCC | endoplasmic reticulum organization | 58/7305 | 87/18723 | 1.59e-07 | 2.61e-06 | 58 |
| GO:00311226 | Oral cavity | OSCC | cytoplasmic microtubule organization | 39/7305 | 56/18723 | 3.29e-06 | 3.93e-05 | 39 |
| GO:00901581 | Oral cavity | OSCC | endoplasmic reticulum membrane organization | 10/7305 | 13/18723 | 6.32e-03 | 2.35e-02 | 10 |
| GO:00106447 | Oral cavity | OSCC | cell communication by electrical coupling | 19/7305 | 32/18723 | 1.56e-02 | 5.00e-02 | 19 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRDN | SNV | Missense_Mutation | c.948N>C | p.Lys316Asn | p.K316N | Q13061 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.888) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| TRDN | SNV | Missense_Mutation | novel | c.1981N>C | p.Val661Leu | p.V661L | Q13061 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
| TRDN | SNV | Missense_Mutation | c.1432N>A | p.Gly478Arg | p.G478R | Q13061 | protein_coding | deleterious_low_confidence(0.03) | benign(0.259) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TRDN | SNV | Missense_Mutation | c.629N>A | p.Thr210Asn | p.T210N | Q13061 | protein_coding | deleterious_low_confidence(0.02) | benign(0.342) | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TRDN | SNV | Missense_Mutation | novel | c.1621N>A | p.His541Asn | p.H541N | Q13061 | protein_coding | deleterious_low_confidence(0.01) | benign(0.081) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRDN | SNV | Missense_Mutation | c.1921N>A | p.Glu641Lys | p.E641K | Q13061 | protein_coding | deleterious_low_confidence(0) | benign(0.321) | TCGA-AR-A1AV-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD | |
| TRDN | SNV | Missense_Mutation | rs201899630 | c.884N>T | p.Pro295Leu | p.P295L | Q13061 | protein_coding | tolerated_low_confidence(0.26) | benign(0.003) | TCGA-B6-A0RQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRDN | SNV | Missense_Mutation | c.382N>G | p.Thr128Ala | p.T128A | Q13061 | protein_coding | tolerated_low_confidence(0.41) | benign(0.138) | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TRDN | SNV | Missense_Mutation | novel | c.2074N>A | p.Val692Ile | p.V692I | Q13061 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.584) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| TRDN | SNV | Missense_Mutation | rs748395950 | c.134N>A | p.Ser45Asn | p.S45N | Q13061 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.998) | TCGA-D8-A1JM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | ChemotherapyHormone Therapy | doxorubicine | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |